Extracellular Biomarkers Summit, March 16-18, 2015  
Extracellular Biomarkers Summit, March 16-18, 2015 

Dinner Short Courses

Monday, March 16, 6:30-9:30 pm

SC1: Systems Biology, Evidence Synthesis and in silico Discovery Approaches to microRNA Biomarkers


Christos Argyropoulos, M.D., Ph.D., Assistant Professor, Nephrology, Department of Internal Medicine, University of New Mexico School of Medicine

John Chevillet, Ph.D., Postdoctoral Research Fellow, Laboratory of Leroy Hood, Institute for Systems Biology

There currently exists no standard systematic way to identify candidate microRNAs for experimental evaluation and verification of their utility as disease biomarkers. In this course we will present a putative framework for the identification of candidate circulating microRNA biomarkers, based on in silico, systems biology and quantitative evidence synthesis techniques. We will discuss the implementation of circulating miRNA studies and examine relevant workflows, specimen collection and handling, quantification and data analysis techniques.

SC2: Executive ThinkTank: Development of Exosome-Based Diagnostics


Peter Yuen, Ph.D., Staff Scientist, Renal Diagnostics & Therapeutics Unit, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health

Clark C. Chen, M.D., Ph.D., Associate Professor and Chief, Stereotactic and Radiosurgery; Vice-Chairman, Academic Affairs, Neurosurgery, University of California, San Diego

Hakho Lee, Ph.D., Assistant Professor, Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School

Radha Munagala, Ph.D., Assistant Professor, Department of Medicine, James Graham Brown Cancer Center, University of Louisville

Qiang Shi, Ph.D., Visiting Scientist, Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration
David T.W. Wong, DMD, DMSc, Professor and Associate Dean of Research, UCLA School of Dentistry; Director, Dental Research Institute

As the demand for more cost-effective treatments increases and the benefit of personalized medicine is clear, the goal of developing accurate, non-invasive diagnostics becomes ever more urgent. Exosomes are especially useful for clinical diagnostics because of their tissue specificity and stability in biofluids, yet issues still remain in their development as diagnostics. What are the optimal methods for isolation and purification? What assays should be used to quantitate exosomal biomarkers? How should exosomal biomarkers be normalized? What theoretical and logistical challenges are bottlenecks for exosomal biomarker development and qualification? These topics and others will be explored in this moderated panel discussion.